Provided is a powder coating latent curing agent; and an epoxy powder coating composition having the same, and more specifically, to a powder coating latent curing agent, which is prepared by hot blending of a product of an addition reaction of imidazole, an amino alcohol and an epoxy resin with a phenolic curing agent resin, is capable of securing latency by inhibiting the reactivity of a phenolic curing agent, is capable of providing an improved coating film appearance and bending resistance when applied as a curing agent to a powder coating, and is capable of improving the workability of a coating preparation; and an epoxy powder coating composition having the same.

Provided is a powder coating latent curing agent; and an epoxy powder coating composition having the same, and more specifically, to a powder coating latent curing agent, which is prepared by hot blending of a product of an addition reaction of imidazole, an amino alcohol and an epoxy resin with a phenolic curing agent resin, is capable of securing latency by inhibiting the reactivity of a phenolic curing agent, is capable of providing an improved coating film appearance and bending resistance when applied as a curing agent to a powder coating, and is capable of improving the workability of a coating preparation; and an epoxy powder coating composition having the same.

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: ##STR00001##
wherein R.sub.1, R.sub.2, R.sub.3, R.sub.5, R.sub.6, W, and A are defined herein.

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: ##STR00001##
wherein R.sub.1, R.sub.2, R.sub.3, R.sub.5, R.sub.6, W, and A are defined herein.

The invention provides compounds that inhibit FTO (fat mass and obesity), including pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof, particularly obesity, with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

The invention provides compounds that inhibit FTO (fat mass and obesity), including pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof, particularly obesity, with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

The present disclosure provides processes for the preparation of a compound of formula: ##STR00001##
which exhibits apoptosis signal-regulating kinase (ASK1) inhibitory activity and is thus useful in the treatment of diseases such as kidney disease, diabetic nephropathy and kidney fibrosis. The disclosure also provides compounds that are synthetic intermediates.

The present disclosure provides processes for the preparation of a compound of formula: ##STR00001##
which exhibits apoptosis signal-regulating kinase (ASK1) inhibitory activity and is thus useful in the treatment of diseases such as kidney disease, diabetic nephropathy and kidney fibrosis. The disclosure also provides compounds that are synthetic intermediates.

The objective of the present invention is to provide a method for producing a carbonate derivative in a safe and efficient manner. The method for producing a carbonate derivative according to the present invention is characterized in comprising irradiating light on a composition containing a C.sub.1-4 halogenated hydrocarbon having one or more kinds of halogen atoms selected from the group consisting of a chlorine atom, a bromine atom and an iodine atom, a nucleophilic functional group-containing compound and the specific base in the presence of oxygen.

Highly active, recoverable and recyclable transition metal-based metathesis catalysts and their organometallic complexes including dendrimeric complexes are disclosed, including a Ru complex bearing a 1,3-dimesityl-4,5-dihydroimidazol-2-ylidene and styrenyl ether ligand. The heterocyclic ligand significantly enhances the catalytic activity, and the styrenyl ether allows for the easy recovery of the Ru complex. Derivatized catalysts capable of being immobilized on substrate surfaces are also disclosed. The present catalysts can be used to catalyze ring-closing metathesis (RCM), ring-opening (ROM) and cross metatheses (CM) reactions, and promote the efficient formation of various trisubstituted olefins at ambient temperature in high yield.